Generalized Myasthenia Gravis
Apr 24, 2026
The gMG Treatment Gold Rush: Key Companies Racing Toward Breakthrough Launches by 2036
Summary Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder, with ~195,000 diagnosed patients across seven major markets in 2025, projected to reach ~250,000 by 2036. Despite recent approvals of FcRn blockers and complement inhibitors, major unmet needs remain, including unpred...
Read More...
Aug 29, 2025
Bridging Today and Tomorrow in Myasthenia Gravis Treatment: A Strategic Review of Marketed Treatments and Developmental Frontiers
Myasthenia gravis is a rare autoimmune neuromuscular disorder marked by fluctuating muscle weakness due to impaired communication between nerves and muscles. Most cases involve autoantibodies against Acetylcholine Receptors (AChRs), reducing their numbers, blocking function, or disrupting alignment, leading to dimi...
Read More...
May 16, 2025
J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis (gMG). This myasthenia gravis drug will be marketed under the name IMAAVY. Although J&J isn’t the first to receive FDA approval for an FcRn-blocking antibody in this indication, the c...
Read More...
Mar 18, 2025
FDA Expands SOLIRIS for Pediatric Myasthenia Gravis; vTv’s Cadisegliatin Program Resumes as FDA Lifts Hold; ENCell’s EN001 Wins Orphan Drug Designation for Charcot-Marie-Tooth; FDA Accepts Sydnexis’ NDA for SYD-101 in Pediatric Myopia; Cambium Bio’s Potency Assay Strategy Cleared for Elate Ocular Phase III Trials
MDA Applauds FDA’s Expanded Approval of Soliris for Pediatric Generalized Myasthenia Gravis The Muscular Dystrophy Association (MDA) celebrates the FDA approval of an expanded indication for Alexion/AstraZeneca’s eculizumab (Soliris), now authorized for pediatric patients aged six and older with generalized myas...
Read More...
Jan 14, 2025
Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer
FDA Accepts Agios’ SNDA for PYRUKYND in Thalassemia Patients Agios Pharmaceuticals, Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) to treat adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The appl...
Read More...
Jul 15, 2024
FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications
Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe? The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players ...
Read More...
Jul 02, 2024
Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR EU CHMP Recommendation; Verona Pharma’s Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval
Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...
Read More...
May 06, 2024
FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach
Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leav...
Read More...
Dec 18, 2023
The Expanding Market of Complement Inhibitors
The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...
Read More...
Oct 24, 2023
FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1
UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
